Showing 8821-8830 of 9459 results for "".
- CMS and AMA Announce Efforts to Ease ICD-10 Transitionhttps://practicaldermatology.com/news/cms-and-ama-announce-efforts-to-ease-icd-10-transition/2458913/The Centers for Medicare & Medicaid Services (CMS) and the American Medical Association (AMA) are initiating efforts to continue to help physicians get ready ahead of the October 1 deadline to move from ICD-9 to ICD-10 coding for medical diagnoses and inpatient hospital procedures. In respons
- Cynosure's SculpSure Receives Expanded FDA Clearance for Lipolysis of the Abdomenhttps://practicaldermatology.com/news/cynosures-sculpsure-receives-expanded-fda-clearance-for-lipolysis-of-the-abdomen/2458914/Cynosure, Inc. has received 510(k) clearance from the FDA to market SculpSure™ for non-invasive lipolysis of the abdomen. In May, the FDA cleared SculpSure for non-invasive lipolysis of the flanks. SculpSure is a safe, clinically proven treatment designed to reduce fat non-invasivel
- Unilever to Acquire Muradhttps://practicaldermatology.com/news/unilever-to-acquire-murad/2458916/Unilever has signed an agreement to acquire Murad. This follows the recent acquisitions of Dermalogica, Kate Somerville, and REN, which jointly position Unilever as a key player in the personal care prestige segment. Murad was founded in 1989 in Los Angeles. Howard Murad MD, a dermatologi
- Restylane Lyft Approved for Cheek Augmentation and Midface Contour Deficiencieshttps://practicaldermatology.com/news/restylane-lyft-approved-for-cheek-augmentation-and-midface-contour-deficiencies/2458917/The FDA approved Galderma's Restylane Lyft for cheek augmentation and the correction of age-related midface contour deficiencies in patients over the age of 21. Restylane Lyft, formerly marketed as Perlane-L, is an injectable gel used to increase volume and smooth wrinkles in the face. With t
- DermatologistOnCall Launches New Mobile Apphttps://practicaldermatology.com/news/dermatologistoncall-launches-new-mobile-app/2458919/DermatologistOnCall launched a new mobile app that it says enables patients to quickly and easily start and complete an online visit with a board-certified dermatologist. The app is free and works with Apple's iPhones and iPads, and Android phones and tablets. "Our new mobile app
- ASDS: Laser Hair Removal On the Risehttps://practicaldermatology.com/news/asds-laser-hair-removal-on-the-rise/2458918/More patients are seeking laser treatments to permanently remove unwanted hair, a new American Society for Dermatologic Surgery (ASDS) survey shows. About 633,000 laser hair removal procedures were performed by ASDS members last year – a 27 percent increase from 2013 and a 51 percen
- SCOTUS Upholds Affordable Care Act in King v. Burwell Ruling; AADA and AMA Issue Statementshttps://practicaldermatology.com/news/scotus-upholds-affordable-care-act-in-king-v-burwell-ruling-aada-and-ama-issue-statements/2458920/In a 6-3 ruling in King v. Burwell, the US Supreme Court upheld tax subsidies for the Affordable Care Act. Steven J. Stack, MD, President of the American Medical Association release a statement on the decision, saying “The American Medical Association (AMA) is relieved that today&rs
- Research Identifies Gene Linked to Melanoma Growth, Worse Outcomeshttps://practicaldermatology.com/news/research-identify-gene-linked-to-melanoma-growth-worse-outcomes/2458925/High levels of a specific protein linked to gene expression are associated with worse outcomes in melanoma, according to a study led by researchers at Icahn School of Medicine at Mount Sinai and published online in the journal Molecular Cell. Research shows that the protein, called H2A.Z.
- BTL Vanquish FDA Cleared for Circumferential Reduction of Abdomen Areahttps://practicaldermatology.com/news/btl-vanquish-fda-cleared-for-circumferential-reduction-of-abdomen-area/2458926/BTL Industries received FDA clearance of its BTL Vanquish device for circumferential reduction of the abdomen area. BTL Vanquish uses a panel array that emits selective RF energy with the largest spot size in the industry t
- Allergan to Acquire Kytherahttps://practicaldermatology.com/news/allergan-to-acquire-kythera/2458927/Allergan has entered into a definitive agreement to acquire Kythera Biopharmaceuticals in a cash and stock transaction valued at $75 per share, or approximately $2.1 billion. Once the transaction is complete, Kythera’s recently approved Kybella (deoxycholic acid) will be part of an aestheti